Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICOLON: SITT vs MITT in COPD
NCT05495698Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Adherence to Inhaled Corticosteroids Therapy at 12 months. Started Dec 2022; status: recruiting.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05495698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495698.